quinoxalines has been researched along with Pituitary Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Cheng, X; Wang, S; Wang, X; Wu, J; Zhang, H; Zhang, Y; Zhu, K | 1 |
| Bao, X; Cai, F; Dai, C; Feng, M; Guo, K; Li, G; Lian, W; Liu, X; Ma, S; Ma, W; Wang, J; Wang, R; Xiao, J; Xing, B; Yang, Y; Yao, Y; Zhang, B; Zhang, H | 1 |
2 other study(ies) available for quinoxalines and Pituitary Neoplasms
| Article | Year |
|---|---|
PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Databases, Genetic; Estrogens; Gene Expression Profiling; Gene Regulatory Networks; Humans; In Vitro Techniques; Indolizines; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pituitary Neoplasms; Prolactin; Prolactinoma; Protein Interaction Maps; Quinoxalines; Rats | 2021 |
Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
Topics: Adenoma; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Female; Human Growth Hormone; Humans; Mice; Mice, Nude; Phosphoinositide-3 Kinase Inhibitors; Pituitary Neoplasms; Prolactin; Proto-Oncogene Proteins c-akt; Quinoxalines; Signal Transduction; Sulfonamides; Temozolomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2013 |